Effect of NK cell therapy in COVID-19

Evaluating the safety and efficacy of allogeneic NK cells on COVID-19 induced pneumonia, double blind, randomized clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200417047113N1

Enrollment

Registered

2020-04-24

Start date

2020-04-27

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: COVID-19. Condition 2: COVID-19. Condition 3: Viral pneumonia. COVID-19, virus identified COVID-19, virus not identified Other viral pneumonia

Interventions

Intervention 1: Intervention group 1: treatment group A, 0.1 * 107 NK cells per kilogram of patient weight. The lowest dose of cells will be injected into this treatment cohort. These patients will be

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: All COVID-19 patients confirmed by CT scan with possitive RT-PCR

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Known HIV, HBV or HCV infection Patients with malignant tumor, other serious systemic diseases and psychosis Diabetic patients Patients who are participating in other clinical trials

Design outcomes

Primary

Measure	Time frame
Fever. Timepoint: Days 1, 3, 7, 14, and 28. Method of measurement: Thermometer.;Number of breathes per minute. Timepoint: Days 1, 3, 7, 14, and 28 after cell injection. Method of measurement: Records of the number of breaths in a minute by Nurse in 3 consecutive minutes.;Pulmonary volume. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Pulmonary capacity. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Airway resistance. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Lung elasticity. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Chest pressure. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Cough. Timepoint: Days 1, 3, 7, 14, and 28 after cell injection. Method of measurement: Records in questionnaire by nurse according to defined qualitative criteria.;Skin disorders. Timepoint: Days 1, 3, 7, 14, and 28. Method of measurement: Records in questionnaire by nurse according to defined qualitative criteria.	—

Measure

Time frame

Fever. Timepoint: Days 1, 3, 7, 14, and 28. Method of measurement: Thermometer.;Number of breathes per minute. Timepoint: Days 1, 3, 7, 14, and 28 after cell injection. Method of measurement: Records of the number of breaths in a minute by Nurse in 3 consecutive minutes.;Pulmonary volume. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Pulmonary capacity. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Airway resistance. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Lung elasticity. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Chest pressure. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Cough. Timepoint: Days 1, 3, 7, 14, and 28 after cell injection. Method of measurement: Records in questionnaire by nurse according to defined qualitative criteria.;Skin disorders. Timepoint: Days 1, 3, 7, 14, and 28. Method of measurement: Records in questionnaire by nurse according to defined qualitative criteria.

—

Secondary

Measure	Time frame
Lymphopenia. Timepoint: Day 7. Method of measurement: Complete blood count.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSahar Shojaei

Middle East Gene Therapy Corporation

S.shojaei@megenetherapy.com+98 21 4478 7327

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026